Adriana Kahn, MD

Articles by Adriana Kahn, MD

Findings from David Rimm, MD, PhD, suggest that there may be an inverse relationship between HER2 and TROP2 expression among patients with breast cancer.

Elucidating the Impact of TROP2 on T-DXd Efficacy in Breast Cancer

December 18th 2025

Findings from David Rimm, MD, PhD, suggest that there may be an inverse relationship between HER2 and TROP2 expression among patients with breast cancer.

Tissue samples collected from patients with breast cancer during treatment may help explore therapy selection and predict toxicities.

Gathering Data to Ascertain Biomarker Specificity in HER2– Breast Cancer

ByAdriana Kahn, MD

December 17th 2025

Tissue samples collected from patients with breast cancer during treatment may help explore therapy selection and predict toxicities.

Latest Updated Articles

Gathering Data to Ascertain Biomarker Specificity in HER2– Breast Cancer
December 17th 2025

Trending on CancerNetwork

FDA Approves Zenocutuzumab in NRG1+ Cholangiocarcinoma Post Systemic Therapy

Daraxonrasib Shows Anti-Tumor Activity in Pretreated RAS+ Pancreatic Cancer

FDA Clears AI Stratification Tool in HR+/HER2– Invasive Breast Cancer

Achieving a “Functional Cure” With Multiple Myeloma Therapy

TIP125 ReDiscover-2, a Phase 3 Study of Zovegalisib (RLY-2608) + Fulvestrant Versus Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-Mutant HR+/ HER2- Breast Cancer Following Recurrence or Progression on or After Treatment With a CDK4/6 Inhibitor (Trial in Progress)